Ascendis Pharma A/S (ASND) Analysts See $-0.90 EPS

March 27, 2018 - By Hazel Jackson

 Ascendis Pharma A/S (ASND) Analysts See $ 0.90 EPS

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-0.90 EPS on March, 28.They anticipate $0.35 EPS change or 63.64 % from last quarter’s $-0.55 EPS. After having $-1.22 EPS previously, Ascendis Pharma A/S’s analysts see -26.23 % EPS growth. The stock decreased 0.02% or $0.01 during the last trading session, reaching $64.31. About 114,175 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 96.01% since March 27, 2017 and is uptrending. It has outperformed by 79.31% the S&P500.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 7 analysts covering Ascendis Pharma (NASDAQ:ASND), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Ascendis Pharma has $78 highest and $28.0 lowest target. $54.29’s average target is -15.58% below currents $64.31 stock price. Ascendis Pharma had 21 analyst reports since September 26, 2016 according to SRatingsIntel. The rating was initiated by Wedbush on Monday, September 26 with “Outperform”. The firm earned “Buy” rating on Monday, September 11 by Wedbush. The stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given on Thursday, September 28 by Wedbush. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Hold” rating by Leerink Swann on Friday, September 1. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by Wedbush on Monday, February 26. On Thursday, February 22 the stock rating was maintained by Credit Suisse with “Buy”. Wedbush maintained the shares of ASND in report on Tuesday, February 6 with “Buy” rating. The firm has “Buy” rating given on Friday, September 22 by Wells Fargo. The stock has “Buy” rating by Bank of America on Tuesday, September 26. On Friday, September 22 the stock rating was maintained by Wedbush with “Buy”.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.67 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.